Plasma-derived product labeling claims
Executive Summary
FDA's Transmissible Spongiform Encephalopathies Advisory Committee will discuss labeling claims for TSE clearance studies for plasma-derived products on Oct. 14. Presumptive transfusion transmissions of variant Creutzfeldt-Jakob Disease and FDA recommended safeguards will also be addressed. The meeting will be held at the Hilton in Silver Spring, Md. beginning at 8 a.m. [To 1watch a webcast or order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...